Canada approves use of Johnson & Johnson's single-shot Covid-19 vaccine

Canada announced its approval of the use of the single-shot Johnson & Johnson Covid-19 vaccine, making it the fourth vaccine that can be administered in the country.

Vaccine
Representative Image
IANS Ottawa
2 min read Last Updated : Mar 06 2021 | 9:24 AM IST

Canada announced its approval of the use of the single-shot Johnson & Johnson Covid-19 vaccine, making it the fourth vaccine that can be administered in the country.

"After a thorough, independent review of the evidence, the Department has determined that the vaccine meets Canada's stringent safety, efficacy and quality requirements," Health Canada said in a statement on Friday, Xinhua news agency reported.

The approval is expected to provide a significant boost to Canada's vaccine rollout. Johnson & Johnson's vaccine is widely seen as one of the easiest to administer because it requires only one dose and can be stored for long periods of time at regular refrigerator temperatures.

The US healthcare giant's vaccine is the fourth to be approved in Canada. Earlier, Canada approved the use of Pfizer-BioNTech, Moderna and AstraZeneca vaccines.

"Canada is the first country to approve four vaccines," said Dr. Supriya Sharma, Health Canada's chief medical advisor, at a press conference Friday morning.

It is approved in Canada for use in individuals aged 18 and older.

Canada has been assessing the Johnson & Johnson shot since November 30 last year.

It has ordered 10 million doses from Johnson & Johnson with options for up to 28 million more. Most of those shots are expected to arrive by the end of September this year.

--IANS

int/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineCoronavirus Tests

First Published: Mar 06 2021 | 9:05 AM IST

Next Story